W Schramm

561 total citations
37 papers, 268 citations indexed

About

W Schramm is a scholar working on Endocrinology, Diabetes and Metabolism, General Health Professions and Oncology. According to data from OpenAlex, W Schramm has authored 37 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 5 papers in General Health Professions and 5 papers in Oncology. Recurrent topics in W Schramm's work include Diabetes Treatment and Management (6 papers), Diabetes Management and Education (5 papers) and Diabetes Management and Research (5 papers). W Schramm is often cited by papers focused on Diabetes Treatment and Management (6 papers), Diabetes Management and Education (5 papers) and Diabetes Management and Research (5 papers). W Schramm collaborates with scholars based in Germany, United States and Switzerland. W Schramm's co-authors include Lutz Heinemann, Kurt Neeser, Bernhard Kulzer, Monika Pobiruchin, Uwe M. Martens, Diethelm Messinger, Uwe Siebert, Christopher G. Parkin, Sylvia Bochum and Hubert Kolb and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Diabetes.

In The Last Decade

W Schramm

34 papers receiving 252 citations

Peers

W Schramm
Willemien Schurer United Kingdom
A Gray United Kingdom
Emelie Andersson Sweden
Jinxiao Lian Hong Kong
Leslie Mallinger United States
Jianchao Quan Hong Kong
Ken Wei Tan Singapore
Irina Odnoletkova Belgium
Jason Black Canada
Willemien Schurer United Kingdom
W Schramm
Citations per year, relative to W Schramm W Schramm (= 1×) peers Willemien Schurer

Countries citing papers authored by W Schramm

Since Specialization
Citations

This map shows the geographic impact of W Schramm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Schramm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Schramm more than expected).

Fields of papers citing papers by W Schramm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Schramm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Schramm. The network helps show where W Schramm may publish in the future.

Co-authorship network of co-authors of W Schramm

This figure shows the co-authorship network connecting the top 25 collaborators of W Schramm. A scholar is included among the top collaborators of W Schramm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Schramm. W Schramm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Schaffer, Kirsten, et al.. (2022). Human-centered Design for a Chronic Disease Management System: An Explorative Case for Cystic Fibrosis. 93. 401–411. 2 indexed citations
3.
4.
Schramm, W, et al.. (2022). A German Smartphone-Based Self-management Tool for Psoriasis: Community-Driven Development and Evaluation of Quality-of-Life Effects. JMIR Formative Research. 6(7). e32593–e32593. 2 indexed citations
5.
Pouwels, Xavier, Chris Sampson, Renée J.G. Arnold, et al.. (2022). Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. Value in Health. 25(4). 473–479. 11 indexed citations
6.
7.
Kent, Seamus, Frauke Becker, Talitha Feenstra, et al.. (2019). The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. PharmacoEconomics. 37(11). 1305–1312. 25 indexed citations
8.
Heinemann, Lutz, et al.. (2019). Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program. Journal of Diabetes Science and Technology. 14(2). 240–249. 18 indexed citations
9.
Kulzer, Bernhard, et al.. (2018). Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program. Diabetes Research and Clinical Practice. 144. 200–212. 42 indexed citations
10.
Pobiruchin, Monika, Sylvia Bochum, Uwe M. Martens, & W Schramm. (2016). Clinical Cancer Registries - Are They Up for Health Services Research?. PubMed. 228. 242–6. 1 indexed citations
11.
Pobiruchin, Monika, Sylvia Bochum, Uwe M. Martens, Meinhard Kieser, & W Schramm. (2016). A method for using real world data in breast cancer modeling. Journal of Biomedical Informatics. 60. 385–394. 16 indexed citations
12.
Pobiruchin, Monika, Sylvia Bochum, Uwe M. Martens, Meinhard Kieser, & W Schramm. (2016). Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset. Data in Brief. 7. 654–657. 2 indexed citations
13.
Schramm, W, et al.. (2012). Regionale Analyse der medikamentösen Behandlungsprävalenz und Arzneimitteltherapie von Diabetes mellitus in Deutschland. DMW - Deutsche Medizinische Wochenschrift. 137(46). 2363–2368. 3 indexed citations
14.
Piehlmeier, W, et al.. (2009). Screening of diabetic patients for microalbuminuria in primary care — The PROSIT-Project. Experimental and Clinical Endocrinology & Diabetes. 107(4). 244–251. 4 indexed citations
15.
Pobiruchin, Monika & W Schramm. (2008). [Does DMP type 2 diabetes mellitus lead to better values of HbA1c and blood pressure? An analysis regarding to published quality reports].. PubMed. 150 Suppl 1. 16–21. 1 indexed citations
16.
Martin, Stéphan, W Schramm, B Schneider, et al.. (2007). Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany (ROSSO 4). Experimental and Clinical Endocrinology & Diabetes. 115(8). 495–501. 35 indexed citations
17.
Neeser, Kurt, et al.. (2004). Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. PharmacoEconomics. 22(5). 321–341. 22 indexed citations
18.
Schramm, W, et al.. (2004). Erkrankungsmodellierung bei Diabetes mellitus. DMW - Deutsche Medizinische Wochenschrift. 129(43). 2305–2310. 1 indexed citations
19.
Krebs, H., et al.. (2003). [The national GTH haemophilia registry as database within the scope of the German human genome project].. PubMed. 23(1). 18–23. 3 indexed citations
20.
Staehler, G., et al.. (1975). [Coagulation disorders in prostatic carcinoma (author's transl)].. PubMed. 14(3). 127–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Willemien Schurer Breakdown of academic impact, for papers by A Gray Breakdown of academic impact, for papers by Emelie Andersson Breakdown of academic impact, for papers by Jinxiao Lian Breakdown of academic impact, for papers by Leslie Mallinger Breakdown of academic impact, for papers by Jianchao Quan Breakdown of academic impact, for papers by Ken Wei Tan Breakdown of academic impact, for papers by Irina Odnoletkova Breakdown of academic impact, for papers by Jason Black
Rankless by CCL
2026